Invitris logo

InvitrisCreating new protein-based drugs at scale

Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.

2023-03-10
Active
Early
W23
6
Healthcare
GermanyEuropeRemotePartly Remote
Invitris screenshot
More About Invitris

Invitris – One System to Conquer All

The Next Generation of Proteins

Key Features

  • Universal platform technology for synthetic protein generation
  • Highest yields and purity through cell-free expression
  • Capability to create novel proteins with unique mechanisms of action
  • Scalable manufacturing processes
  • Focus on both prokaryotic and eukaryotic cell-free expression systems

Use Cases

  • Human therapeutics
  • Industrial applications
  • Agriculture
  • Animal health
  • Food industry
  • Industrial chemistry

Pricing

Contact us for detailed pricing information tailored to your specific needs and use cases.

Teams

Invitris partners with other companies to create and manufacture new products. Our team specializes in:

  • Phages
  • Tailocins
  • Endolysins
  • Neoantigens
  • Vaccines
  • Antibodies
  • Toxic proteins (e.g., nucleases and proteases)

Our expertise spans across various industries, including human health, agriculture, animal health, food, and industrial chemistry.